The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This retrospective study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease. Between 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m2, 2 days), ifosfamide (2 g/m2, 5 days), and etoposide (100 mg/m2, 3 days) every 3 weeks. The primary endpoint was overall response, and the secondary endpoint was adverse events of this regimen. Responses to this regimen according to RECIST criteria were partial response (n = 9, 36%), stable disease (n = 9, 36%) and progressive disease (n = 7, 28%). During the treatment phase, frequent grade 3 or worse adverse events were hematological toxicities including white blood cell decreases (96%), febrile neutropenia (68%), anemia (68%), and platelet count decreases (48%). No long-term adverse events were reported during the study period. This regimen was comparable to previously published doxorubicin-based combination chemotherapy in terms of response rate. Although there were no long-lasting adverse events, based on our results, severe hematological toxicity should be considered.

中文翻译：

---

吡柔比星，异环磷酰胺和依托泊苷联合化疗对软组织肉瘤的疗效：单中心回顾性分析。

软组织肉瘤的标准化疗方案是基于阿霉素的。这项回顾性研究旨在评估吡柔比星，异环磷酰胺和依托泊苷联合治疗该病患者的疗效和安全性。在2008年至2017年之间，每3周用吡柔比星（30 mg / m2，2天），异环磷酰胺（2 g / m2，5天）和依托泊苷（100 mg / m2，3天）治疗25例软组织肉瘤患者。主要终点为总体反应，次要终点为该方案的不良事件。根据RECIST标准对该方案的反应为部分反应（n = 9、36％），稳定疾病（n = 9、36％）和进行性疾病（n = 7、28％）。在治疗阶段，常见的3级或更严重的不良事件是血液毒性，包括白细胞减少（96％），高热性中性粒细胞减少症（68％），贫血（68％）和血小板计数减少（48％）。研究期间未报告长期不良事件。就反应率而言，该方案与以前发表的基于阿霉素的联合化疗相当。尽管没有长期的不良事件，但根据我们的结果，应考虑严重的血液学毒性。